临床特征 | FGFRs突变组 | FGFRs野生组 |
总人数 | 149 | 1422 |
生产状态 |
| |
存活 | 91 (61.1%) | 685 (48.2%) |
死亡 | 58 (38.9%) | 737 (51.8%) |
年龄 |
| |
<50 | 16 (10.7%) | 249 (17.5%) |
>=50 | 133 (89.3%) | 1173 (82.5%) |
性别 |
| |
男 | 99 (66.4%) | 889 (62.5%) |
女 | 50 (33.6%) | 533 (37.5%) |
治疗方式 |
| |
PD-1/PDL-1抑制剂 | 116 (77.9%) | 1113 (78.3%) |
CTLA4抑制剂 | 11 (7.4%) | 87 (6.1%) |
联合治疗 | 22 (14.7%) | 222 (15.6%) |